{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:08:22Z","timestamp":1776406102278,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04017-7","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:30:30Z","timestamp":1775529030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-895X","authenticated-orcid":false,"given":"Nasim","family":"Jaberi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3346-6846","authenticated-orcid":false,"given":"Somayeh","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7885-8643","authenticated-orcid":false,"given":"Farhad","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5583-5561","authenticated-orcid":false,"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"4017_CR1","doi-asserted-by":"publisher","unstructured":"Liu J, Guo M, Ke L et al Cost-Effectiveness of Elbasvir\/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Front public health. 2022;10. https:\/\/doi.org\/10.3389\/fpubh.2022.836986","DOI":"10.3389\/fpubh.2022.836986"},{"issue":"8","key":"4017_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns MP, Maasoumy B (2022) Breakthroughs in hepatitis C research: from discovery to cure. Nat reviews Gastroenterol Hepatol 19(8):533\u2013550. https:\/\/doi.org\/10.1038\/s41575-022-00608-8","journal-title":"Nat reviews Gastroenterol Hepatol"},{"issue":"10100","key":"4017_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/s0140-6736(17)31833-0","volume":"390","author":"GM Collaborators","year":"2017","unstructured":"Collaborators GM (2017) Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1084\u20131150. https:\/\/doi.org\/10.1016\/s0140-6736(17)31833-0","journal-title":"Lancet"},{"key":"4017_CR4","unstructured":"WHO. Global hepatitis report 2024: action for access in low- and middle-income countries. Global HIV, Hepatitis and STIs Programmes (HHS), Health Product Policy and Standards (HPS): World Health Organization (2024) Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672"},{"key":"4017_CR5","unstructured":"WHO. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva. Global HIV, Hepatitis and STIs Programmes (HHS), Guidelines Review Committee: World Health Organization (2022) Available from: https:\/\/www.who.int\/publications\/i\/item\/ 9789240052734"},{"key":"4017_CR6","unstructured":"WHO, Hepatitis C, World Health O (2021) Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"issue":"5","key":"4017_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14737167.2024.2348053","volume":"24","author":"A Shetty","year":"2024","unstructured":"Shetty A, Lee M, Valenzuela J et al (2024) Cost effectiveness of hepatitis C direct acting agents. Expert Rev Pharmacoeconomics Outcomes Res 24(5):589\u2013597. https:\/\/doi.org\/10.1080\/14737167.2024.2348053","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"8","key":"4017_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/jvh.13295","volume":"27","author":"NZ Janjua","year":"2020","unstructured":"Janjua NZ, Wong S, Darvishian M et al (2020) The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat 27(8):781\u2013793. https:\/\/doi.org\/10.1111\/jvh.13295","journal-title":"J Viral Hepat"},{"issue":"8","key":"4017_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/apt.13775","volume":"44","author":"R Faria","year":"2016","unstructured":"Faria R, Woods B, Griffin S et al (2016) Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Aliment Pharmacol Ther 44(8):866\u2013876. https:\/\/doi.org\/10.1111\/apt.13775","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"4017_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.37765\/ajmc.2020.42397","volume":"26","author":"J Jung","year":"2020","unstructured":"Jung J, Du P, Feldman R et al (2020) Discontinuation of new hepatitis C drugs among Medicare patients. Am J Manag Care 26(2):84\u201388. https:\/\/doi.org\/10.37765\/ajmc.2020.42397","journal-title":"Am J Manag Care"},{"issue":"7","key":"4017_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Park H, Henry L et al (2016) Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 150(7):1599\u20131608. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.039","journal-title":"Gastroenterology"},{"key":"4017_CR12","unstructured":"WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Global HIV, Hepatitis and STIs Programmes (HHS), Guidelines Review Committee: World Health Organization (2018) Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241550345"},{"issue":"21","key":"4017_CR13","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas DL (2019) Global elimination of chronic hepatitis. N Engl J Med 380(21):2041\u20132050. https:\/\/doi.org\/10.1056\/NEJMra1810477","journal-title":"N Engl J Med"},{"issue":"5","key":"4017_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"S Blach","year":"2022","unstructured":"Blach S, Terrault NA, Tacke F et al (2022) Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 7(5):396\u2013415. https:\/\/doi.org\/10.1016\/S2468-1253(21)00472-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4017_CR15","unstructured":"Jung JK, Feldman R, Cheong C et al (2016) Coverage for hepatitis C drugs in Medicare Part D. Am J Manag Care. ;22(6 Spec No.):Sp220-6."},{"issue":"1","key":"4017_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12913-021-07289-0","volume":"22","author":"S Boyer","year":"2022","unstructured":"Boyer S, Baudoin M, Nishimwe ML et al (2022) Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. BMC Health Serv Res 22(1):303. https:\/\/doi.org\/10.1186\/s12913-021-07289-0","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"4017_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/jvh.12704","volume":"24","author":"M Buti","year":"2017","unstructured":"Buti M, Dom\u00ednguez-Hern\u00e1ndez R, Oyag\u00fcez I et al (2017) Cost-effectiveness analysis of ledipasvir\/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepatitis 24(9):750\u2013758. https:\/\/doi.org\/10.1111\/jvh.12704","journal-title":"J Viral Hepatitis"},{"issue":"4","key":"4017_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40273-015-0356-x","volume":"34","author":"I Fraser","year":"2016","unstructured":"Fraser I, Burger J, Lubbe M et al (2016) Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. PharmacoEconomics 34(4):403\u2013417. https:\/\/doi.org\/10.1007\/s40273-015-0356-x","journal-title":"PharmacoEconomics"},{"key":"4017_CR19","doi-asserted-by":"publisher","unstructured":"Tasavon Gholamhoseini M, Sharafi H, Hl Borba H et al (2022) Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 12(6). https:\/\/doi.org\/10.1136\/bmjopen-2021-058757","DOI":"10.1136\/bmjopen-2021-058757"},{"issue":"3","key":"4017_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4166\/kjg.2023.141","volume":"83","author":"HD Shin","year":"2024","unstructured":"Shin HD, Song IH, Lee SH et al (2024) Comparison of Glecaprevir\/Pibrentasvir and Sofosbuvir\/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea. Korean J Gastroenterol 83(3):111\u2013118. https:\/\/doi.org\/10.4166\/kjg.2023.141","journal-title":"Korean J Gastroenterol"},{"issue":"8284","key":"4017_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. theBmj 372(8284):1\u20139. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"theBmj"},{"issue":"1","key":"4017_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ et al (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Managed Care Pharm 9(1):53\u201361","journal-title":"J Managed Care Pharm"},{"issue":"2","key":"4017_CR23","doi-asserted-by":"publisher","first-page":"e0246080","DOI":"10.1371\/journal.pone.0246080","volume":"16","author":"C Min","year":"2021","unstructured":"Min C, Xue M, Haotian F et al (2021) An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics. PLoS ONE 16(2):e0246080. https:\/\/doi.org\/10.1371\/journal.pone.0246080","journal-title":"PLoS ONE"},{"issue":"1","key":"4017_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oid\/ofw266","volume":"4","author":"BP Linas","year":"2017","unstructured":"Linas BP, Morgan JR, Pho MT et al (2017) Cost effectiveness and cost containment in the Era of interferon-free therapies to treat hepatitis C virus genotype 1. Open Forum Infect Dis 4(1):1\u201311. https:\/\/doi.org\/10.1093\/oid\/ofw266","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"4017_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13696998.2016.1176030","volume":"19","author":"S Saab","year":"2016","unstructured":"Saab S, Paris\u00e9 H, Virabhak S et al (2016) Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ 19(8):795\u2013805. https:\/\/doi.org\/10.1080\/13696998.2016.1176030","journal-title":"J Med Econ"},{"issue":"2","key":"4017_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.28327","volume":"63","author":"AP Chidi","year":"2016","unstructured":"Chidi AP, Rogal S, Bryce CL et al (2016) Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C. Hepatology 63(2):428\u2013436. https:\/\/doi.org\/10.1002\/hep.28327","journal-title":"Hepatology"},{"issue":"1","key":"4017_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","volume":"176","author":"HS Chahal","year":"2016","unstructured":"Chahal HS, Marseille EA, Tice JA et al (2016) Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 176(1):65\u201373. https:\/\/doi.org\/10.1001\/jamainternmed.2015.6011","journal-title":"JAMA Intern Med"},{"key":"4017_CR28","doi-asserted-by":"publisher","unstructured":"Liu S, Barnett PG, Lo J et al (2016) Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM Policy Pract 1(1). https:\/\/doi.org\/10.1177\/2381468316671946","DOI":"10.1177\/2381468316671946"},{"issue":"1","key":"4017_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","volume":"37","author":"I Kawaguchi","year":"2020","unstructured":"Kawaguchi I, Chayama K, Gonzalez YS et al (2020) A Cost-Effectiveness Analysis of Glecaprevir\/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Therapy 37(1):457\u2013476. https:\/\/doi.org\/10.1007\/s12325-019-01166-3","journal-title":"Adv Therapy"},{"key":"4017_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2016.10.002","volume":"12","author":"T Ward","year":"2017","unstructured":"Ward T, Webster S, Mishina S et al (2017) Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir\u2009+\u2009Asunaprevir and Sofosbuvir\/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues 12:1\u20136. https:\/\/doi.org\/10.1016\/j.vhri.2016.10.002","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"4017_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/03007995.2016.1222513","volume":"33","author":"A Igarashi","year":"2017","unstructured":"Igarashi A, Tang W, Guerra I et al (2017) Cost-utility analysis of ledipasvir\/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin 33(1):11\u201321. https:\/\/doi.org\/10.1080\/03007995.2016.1222513","journal-title":"Curr Med Res Opin"},{"key":"4017_CR32","doi-asserted-by":"publisher","unstructured":"Goudarzi Z, Poursamad A, Karimzadeh I et al (2021) Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C. Hepat Monthly 21(8). https:\/\/doi.org\/10.5812\/hepatmon118646","DOI":"10.5812\/hepatmon118646"},{"key":"4017_CR33","doi-asserted-by":"publisher","first-page":"779215","DOI":"10.3389\/fpubh.2021.779215","volume":"9","author":"HJ Zhou","year":"2021","unstructured":"Zhou HJ, Cao J, Shi H et al (2021) Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front public health 9:779215. https:\/\/doi.org\/10.3389\/fpubh.2021.779215","journal-title":"Front public health"},{"key":"4017_CR34","doi-asserted-by":"publisher","unstructured":"Stahmeyer JT, Rossol S, Liersch S et al (2017) Cost-effectiveness of treating hepatitis c with sofosbuvir\/ledipasvir in Germany. PLoS ONE 12(1). https:\/\/doi.org\/10.1371\/journal.pone.0169401","DOI":"10.1371\/journal.pone.0169401"},{"issue":"9","key":"4017_CR35","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","volume":"23","author":"OT Due","year":"2020","unstructured":"Due OT, Thakkinstian A, Thavorncharoensap M et al (2020) Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value Health 23(9):1180\u20131190. https:\/\/doi.org\/10.1016\/j.jval.2020.03.018","journal-title":"Value Health"},{"issue":"6","key":"4017_CR36","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/hep.32053","volume":"74","author":"MS Sulkowski","year":"2021","unstructured":"Sulkowski MS, Moon JS, Sherman KE et al (2021) A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology 74(6):2952\u20132964. https:\/\/doi.org\/10.1002\/hep.32053","journal-title":"Hepatology"},{"issue":"6","key":"4017_CR37","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/hep.27724","volume":"61","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Marcellin P et al (2015) Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION\u20101, \u20102, and \u20103 clinical trials. Hepatology 61(6):1798\u20131808. https:\/\/doi.org\/10.1002\/hep.27724","journal-title":"Hepatology"},{"issue":"9","key":"4017_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jvh.13716","volume":"29","author":"DM Evon","year":"2022","unstructured":"Evon DM, Dong M, Reeve BB et al (2022) Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir\/sofosbuvir versus elbasvir\/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. J Viral Hepat 29(9):795\u2013806. https:\/\/doi.org\/10.1111\/jvh.13716","journal-title":"J Viral Hepat"},{"issue":"4","key":"4017_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/gutjnl-2017-315906","volume":"68","author":"G Shiha","year":"2019","unstructured":"Shiha G, Esmat G, Hassany M et al (2019) Ledipasvir\/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 68(4):721\u2013728. https:\/\/doi.org\/10.1136\/gutjnl-2017-315906","journal-title":"Gut"},{"issue":"4","key":"4017_CR40","first-page":"256","volume":"40","author":"D Gritsenko","year":"2015","unstructured":"Gritsenko D, Hughes G (2015) Ledipasvir\/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P t 40(4):256\u2013276","journal-title":"P t"},{"key":"4017_CR41","doi-asserted-by":"publisher","DOI":"10.4274\/vhd.galenos.2021.2021-6-1","author":"M Pekg\u00f6z","year":"2021","unstructured":"Pekg\u00f6z M, \u0130nce N (2021) The Treatment of Ledipasvir\/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-up. Viral Hepat J. https:\/\/doi.org\/10.4274\/vhd.galenos.2021.2021-6-1","journal-title":"Viral Hepat J"},{"issue":"64","key":"4017_CR42","first-page":"S810","volume":"2","author":"P Buggisch","year":"2016","unstructured":"Buggisch P, B\u00f6ker K, G\u00fcnther R et al (2016) Ledipasvir\/sofosbuvir treatment for 8 weeks in treatment-na\u00efve HCV genotype 1 infected patients under real life conditions: data from the German Hepatitis C-Registry (DHC-R). J Hepatol 2(64):S810","journal-title":"J Hepatol"},{"issue":"64","key":"4017_CR43","doi-asserted-by":"publisher","first-page":"S809","DOI":"10.1016\/S0168-8278(16)01580-4","volume":"2","author":"P Buggisch","year":"2016","unstructured":"Buggisch P, Wursthorn K, Stoehr A et al (2016) Real-World Effectiveness and Cost per Sustained Viral Response of Ledipasvir\/Sofosbuvir Chronic Hepatitis C Treatment. J Hepatol 2(64):S809\u2013S10","journal-title":"J Hepatol"},{"issue":"64","key":"4017_CR44","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/S0168-8278(16)00188-4","volume":"2","author":"J Crespo","year":"2016","unstructured":"Crespo J, Fenandez I, Cabezas J et al (2016) Effectiveness and safety of sofosbuvir\/ledipasvir treatment for monoinfected genotype 1 HCV patients in real-life clinical practice: results from Spanish Hepa-C Cohort. J Hepatol 2(64):S217\u2013S8","journal-title":"J Hepatol"},{"issue":"3","key":"4017_CR45","doi-asserted-by":"publisher","first-page":"A313","DOI":"10.1016\/j.jval.2016.03.992","volume":"19","author":"M Curry","year":"2016","unstructured":"Curry M, Bacon B, Dieterich D et al (2016) Effectiveness of 8 or 12 week LDV\/SOF in treatment-na\u00efve patients with non-cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network. Value Health 19(3):A313","journal-title":"Value Health"},{"issue":"1","key":"4017_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12985-021-01625-w","volume":"18","author":"X Yang","year":"2021","unstructured":"Yang X, Tang Y, Xu D et al (2021) Efficacy and safety of ledipasvir\/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 18(1):156. https:\/\/doi.org\/10.1186\/s12985-021-01625-w","journal-title":"Virol J"},{"key":"4017_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijid.2016.12.023","volume":"55","author":"T Tao","year":"2017","unstructured":"Tao T, Jiang X, Chen Y et al (2017) Efficacy and Safety of Ledipasvir\/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Int J Infect Dis 55:56\u201371. https:\/\/doi.org\/10.1016\/j.ijid.2016.12.023","journal-title":"Int J Infect Dis"},{"issue":"2","key":"4017_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5604\/16652681.1231577","volume":"16","author":"MS Rezaee-Zavareh","year":"2017","unstructured":"Rezaee-Zavareh MS, Hesamizadeh K, Behnava B et al (2017) Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: systematic review and meta-analysis. Ann Hepatol 16(2):188\u2013197. https:\/\/doi.org\/10.5604\/16652681.1231577","journal-title":"Ann Hepatol"},{"issue":"12","key":"4017_CR49","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/17474124.2018.1540929","volume":"12","author":"J Puig-Junoy","year":"2018","unstructured":"Puig-Junoy J, Pascual-Argente N, Puig-Codina L et al (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 12(12):1251\u20131263. https:\/\/doi.org\/10.1080\/17474124.2018.1540929","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"4017_CR50","first-page":"A183","volume":"20","author":"M Alowairdhi","year":"2017","unstructured":"Alowairdhi M (2017) The cost-effectiveness of the new direct acting antivirals in the treatment of chronic hepatitis c genotype 1 and genotype 4: A systematic review. Value Health 20(5):A183","journal-title":"Value Health"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04017-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04017-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04017-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:37Z","timestamp":1776404257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04017-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04017-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Iran University of Medical Sciences approved the study, and the reference number is IR.IUMS.REC.1402.1147.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}